AudioScholar Dermatology Weekly (India)

Editor's Pick: Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials (Nature Medicine, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapy for chronic inflammatory skin disease, the rising burden of bullous pemphigoid, and pediatric care alongside treatment resistance in scabies and melanoma. Let's dive in.

This week's papers:

1. Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials.. Nature Medicine 2026
2. Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
3. Dupilumab in Atopic Dermatitis - Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry.. Acta Dermato-Venereologica 2026
4. End-of-Dose Effect as a Guide for Biologic Optimization in Hidradenitis Suppurativa.. JAMA Dermatology 2026
5. Increased incidence and healthcare burden of bullous pemphigoid: A population-based cohort study.. Journal of the European Academy of Dermatology and Venereology 2026
6. Dipeptidyl Peptidase-4 Inhibitors and Bullous Pemphigoid: A Danish Nationwide Case-Control Study.. Dermatology 2026
7. Clinical Outcomes of Nasal Tip Infantile Hemangiomas: A Retrospective Cohort Study.. Pediatric Dermatology 2026
8. Expert Recommendations for Use of Combined Oral Contraceptives in Preadolescent and Young Adolescent Patients With Acne Vulgaris.. Pediatric Dermatology 2026
9. Ineffectiveness of permethrin in human scabies treatment: A multicenter study of kdr gene mutations.. Journal of the European Academy of Dermatology and Venereology 2026
10. Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.. Nature Medicine 2026

Listen at AudioScholar

Editor's Pick: 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study (Journal of the American Academy of Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and immunotherapy, long-term management of inflammatory skin disease, and the harder edges of blistering, metabolic and genetic skin conditions. Let's dive in.

This week's papers:

1. Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 trial.. Nature Medicine 2026
2. Intralesional cemiplimab for patients with early-stage cutaneous squamous cell carcinoma: Results from a dose-escalation study with expansion cohorts.. Journal of the American Academy of Dermatology 2026
3. Targeted and Immune-Based Therapies in Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis.. JAMA Dermatology 2026
4. A randomised double-blind placebo-controlled trial of topical menthol for pain relief during photodynamic therapy.. Clinical and Experimental Dermatology 2026
5. 52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study.. Journal of the American Academy of Dermatology 2026
6. Phenome-wide Longitudinal Association Study of Hospital-recorded Comorbidity in Psoriasis.. British Journal of Dermatology 2026
7. Vitamin D status and systemic inflammatory burden as a predictor of biologic treatment response in psoriasis -A pilot study in Northern Ireland.. Clinical and Experimental Dermatology 2026
8. Site-Specific Treatment and Remission Patterns in Multisite Mucous Membrane Pemphigoid.. JAMA Dermatology 2026
9. Estrogen Use and Porphyria Cutanea Tarda.. JAMA Dermatology 2026
10. Understanding the Experiences and Needs of Parents With Children With Epidermolysis Bullosa. A Qualitative Study to Inform the Development of a Self-help Toolkit.. British Journal of Dermatology 2026

Listen at AudioScholar

Editor's Pick: Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa (Journal of the American Academy of Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning a major push in hidradenitis suppurativa, new targeted therapies and treatment selection in inflammatory skin disease, and risk stratification and staging in skin cancer. Let's dive in.

This week's papers:

1. Joint American Academy of Dermatology-Hidradenitis Suppurativa Foundation guidelines of care for the management of hidradenitis suppurativa.. Journal of the American Academy of Dermatology 2026
2. HiSQOL-mini: Development and Validation of a Shortened Version of the Hidradenitis Suppurativa Quality of Life (HiSQOL) Instrument.. British Journal of Dermatology 2026
3. Optimizing surgery in hidradenitis suppurativa.. Journal of the European Academy of Dermatology and Venereology 2026
4. Hidradenitis suppurativa skin microbiome: In-depth analysis and modulation by systemic therapies.. Journal of the European Academy of Dermatology and Venereology 2026
5. Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.. Journal of the American Academy of Dermatology 2026
6. Efficacy and safety of QY201, an oral dual Janus kinase 1/tyrosine kinase 2 inhibitor, in adults with moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2 dose-finding trial.. Journal of the American Academy of Dermatology 2026
7. Psoriasis: Which therapy for which patient, updated, part I. Focus on Psoriasis Comorbidities and Preferred Systemic Agents.. Journal of the American Academy of Dermatology 2026
8. Psoriasis: Which therapy for which patient, updated, part II. Focus on special populations and chronic infections.. Journal of the American Academy of Dermatology 2026
9. Evaluating the Performance of Melanoma Risk Prediction Models.. JAMA Dermatology 2026
10. Extramammary Paget's Disease With Bilateral Sentinel Lymph Node Biopsy: a Multicenter Study of Lymphatic Patterns and Outcomes.. Clinical and Experimental Dermatology 2026

Listen at AudioScholar

Editor's Pick: Cancer Risk in Patients With Overall and Site-Specific Lichen Planus (JAMA Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cancer risk in chronic inflammatory dermatoses and melanoma diagnostics, the expanding role of JAK inhibition and phototherapy in pigmentary and sclerosing disease, and fresh evidence on diagnosing and managing blistering, flushing and follicular inflammatory conditions. Let's dive in.

This week's papers:

1. Cancer Risk in Patients With Overall and Site-Specific Lichen Planus.. JAMA Dermatology 2026
2. Female genital lichen sclerosus.. Journal of the European Academy of Dermatology and Venereology 2026
3. Experience-based recommendations for the diagnosis and management of early-stage nail unit melanoma.. Journal of the European Academy of Dermatology and Venereology 2026
4. Real-time assessment of mitotic rate in malignant melanoma by ex vivo confocal microscopy.. Clinical and Experimental Dermatology 2026
5. Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo: A Single-Center Prospective Study.. Clinical and Experimental Dermatology 2026
6. Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.. Journal of Investigative Dermatology 2026
7. UVA1 Phototherapy in a national reference center:A 10-year systematical analysis.. Dermatology 2026
8. LABD97 IgG ELISA increases sensitivity of ELISA serologic testing for the diagnosis of bullous pemphigoid.. Journal of the American Academy of Dermatology 2026
9. Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial.. JAMA Dermatology 2026
10. Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target.. Journal of the European Academy of Dermatology and Venereology 2026

Listen at AudioScholar

Editor's Pick: Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome (JAMA Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cutaneous oncology and prevention, autoimmune blistering disease, and the expanding therapeutic toolkit for chronic inflammatory skin disease. Let's dive in. We start with skin cancer, where this week's papers look at better ways to judge prognosis, choose drugs, and prevent disease in high-risk families.

This week's papers:

1. Cutaneous Lymphoma International Prognostic Index and Risk Stratification in Advanced Mycosis Fungoides and Sézary Syndrome.. JAMA Dermatology 2026
2. Comparison of efficacy and tolerability of hedgehog pathway inhibitors for locally advanced basal cell carcinoma: An expert opinion in the new age of immunotherapy.. Journal of the American Academy of Dermatology 2026
3. Melanoma Prevention Among Children of Melanoma Survivors: A Randomized Clinical Trial.. JAMA Dermatology 2026
4. Pemphigoid After Immune Checkpoint Inhibitors and Other Anti-Neoplastic Medications: A Danish Nationwide Case-Control Study.. Clinical and Experimental Dermatology 2026
5. Targeted therapies in pemphigus vulgaris: Emerging horizons beyond rituximab.. Journal of the European Academy of Dermatology and Venereology 2026
6. Assessment of the Sustained Response to Systemic Treatment for Atopic Dermatitis in Patients Who Achieved Disease Remission: A Systematic Review and Network Meta-Analysis Comparing Withdrawal, Dose Reduction and Dosing Interval Extension Versus Continuation Therapy.. British Journal of Dermatology 2026
7. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.. Acta Dermato-Venereologica 2026
8. Effect of Biologic Therapy on Depression and Anxiety Symptoms in Patients With Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis.. British Journal of Dermatology 2026
9. Upcoming novel treatments for hidradenitis suppurativa: An overview of the pipeline.. Journal of the European Academy of Dermatology and Venereology 2026
10. Dupilumab as Add-On Therapy for JAK Inhibitor-Relapsed Pediatric Alopecia Areata: A Case Series.. Pediatric Dermatology 2026

Listen at AudioScholar

Editor's Pick: Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA) (Journal of the American Academy of Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning skin cancer and immunotherapy, immune-related toxicities, and practical consensus guidance for infections, inflammatory disease and hair loss. Let's dive in. We start with cutaneous oncology, where two large datasets are sharpening how we stage and treat.

This week's papers:

1. Five-year survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).. Nature Medicine 2026
2. Collaborative Multicenter Prognostication and Staging System for Cutaneous Squamous Cell Carcinoma (COMPASS-SCC).. Journal of the American Academy of Dermatology 2026
3. Autoimmune Bullous Disorders Associated With Immune Checkpoint Inhibitors: A Retrospective Review of a Single Center Cohort Over the Past Decade.. Clinical and Experimental Dermatology 2026
4. Immune-related adverse events with mogamulizumab in cutaneous T-cell lymphoma: A multicentre study.. Journal of the European Academy of Dermatology and Venereology 2026
5. Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa: a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA).. Journal of the American Academy of Dermatology 2026
6. IADVL consensus recommendations on Trichophyton indotineae infections: Using modified Delphi method.. Journal of the European Academy of Dermatology and Venereology 2026
7. A single-dose topical therapy cures scabies in a human-relevant porcine model.. Science Translational Medicine 2026
8. Summary of Best Evidence for Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.. Acta Dermato-Venereologica 2026
9. Low-Dose Oral Minoxidil Use for Pediatric Hair Disorders: An International Consensus Statement.. JAMA Dermatology 2026
10. A Clinical Approach to Psychodermatologic Conditions: From Recognition to Treatment.. Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Editor's Pick: Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial (JAMA Dermatology, 2026)

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning psoriasis across the lifespan, targeted small molecules moving into orphan inflammatory dermatoses, and the less glamorous but equally consequential business of timing, access, and risk stratification. Let's dive in. We'll start with psoriasis, where two papers look at opposite ends of the treatment arc.

This week's papers:

1. Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.. British Journal of Dermatology 2026
2. Clinical characteristics and risk factors for a distinct pustular psoriasis flare after withdrawal of biologics in plaque psoriasis.. Journal of the American Academy of Dermatology 2026
3. Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial.. JAMA Dermatology 2026
4. Upadacitinib for Palmoplantar Pustulosis: An Open-label, Assessor-blinded Feasibility Study Using Historic Control Data (JAKPPPOT).. British Journal of Dermatology 2026
5. Janus Kinase Inhibitor Use in Adults Aged 65 Years and Older: A Clinical Review Across Atopic Dermatitis, Alopecia Areata, and Psoriasis.. Journal of the American Academy of Dermatology 2026
6. Early systemic intervention for vitiligo: A prospective bicentric interventional study.. Journal of the European Academy of Dermatology and Venereology 2026
7. Chronic Spontaneous Urticaria in Finland - A Nationwide Registry Study on Epidemiology and Treatment Patterns in Secondary Care.. Acta Dermato-Venereologica 2026
8. Consensus recommendations for Trichophyton indotineae: A modified Delphi study.. Journal of the European Academy of Dermatology and Venereology 2026
9. Best Practices for Managing Pseudofolliculitis Barbae: An Expert Consensus Delphi Study.. JAMA Dermatology 2026
10. Skin Cancer Risk Stratification and Outcomes in Swedish Solid Organ Transplant Recipients.. Journal of Investigative Dermatology 2026

Listen at AudioScholar

Editor's Pick: Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data (British Journal of Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the comparative safety and durability of biologics in inflammatory skin disease, the real-world performance of our immunomodulatory workhorses in severe and rare conditions, and a group of studies on comorbidity screening and risk stratification. Let's dive in.

This week's papers:

1. Risks of tuberculosis, meningitis, candidiasis, and fungal infections among patients receiving systemic treatments for psoriasis: a nationwide cohort study from BADBIR data.. British Journal of Dermatology 2026
2. Real-World Treatment Response to Adalimumab and Secukinumab in Chinese Adults with Hidradenitis Suppurativa: A Retrospective Cohort Study.. Dermatology 2026
3. Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis.. JAMA Dermatology 2026
4. Short-term prognostic factors of rituximab combined with glucocorticoids in the treatment of pemphigus: A multicenter retrospective study.. Journal of the American Academy of Dermatology 2026
5. Adverse Events and Real-World Outcomes of Intravenous Immunoglobulin in Dermatologic Diseases: A 20-Year Cohort Study.. Clinical and Experimental Dermatology 2026
6. Updosed Omalizumab in Chronic Spontaneous Urticaria With or Without Symptomatic Dermographism.. Clinical and Experimental Dermatology 2026
7. Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion.. Journal of the European Academy of Dermatology and Venereology 2026
8. Adverse pregnancy outcomes in women with atopic dermatitis: A systematic review and meta-analysis.. Journal of the European Academy of Dermatology and Venereology 2026
9. Systematic Review and Meta-Analysis of Thyroid Disease in Children With Vitiligo.. Pediatric Dermatology 2026
10. Precision Medicine for Somatic Mutation-Driven Vascular Anomalies.. British Journal of Dermatology 2026

Listen at AudioScholar

Editor's Pick: Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study (British Journal of Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning immune-targeted therapy — where one major trial failed and several others refine how we use the drugs we already have — plus skin cancer surgery and systemic comorbidity, and a final group on infection, prevention and how care gets delivered. Let's dive in.

This week's papers:

1. Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.. British Journal of Dermatology 2026
2. Dose optimization of deuruxolitinib in adults with alopecia areata: A phase 2 randomized trial.. Journal of the American Academy of Dermatology 2026
3. Pediatric Alopecia Areata and JAK Inhibitors: Bridging the Gap Between Evidence and Practice.. Journal of the American Academy of Dermatology 2026
4. Drug Survival of Omalizumab and Factors Associated With Discontinuation in Chronic Urticaria: A Meta-Analysis.. JAMA Dermatology 2026
5. Inflammatory Bowel Disease and Interleukin-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.. JAMA Dermatology 2026
6. Five-year Recurrence Rate of Cutaneous Squamous Cell Carcinoma After Mohs Micrographic Surgery Versus Standard Excision: a Prospective Multicentre Cohort Study.. British Journal of Dermatology 2026
7. Blood proteomics links systemic inflammation with early atherosclerosis in moderate-to-severe atopic dermatitis.. Journal of Investigative Dermatology 2026
8. Advances in the diagnosis and management of skin and soft tissue infections.. BMJ 2026
9. Comparison of sunscreen products for babies and children with those for adults.. Dermatology 2026
10. Veterans' Willingness to Use Home-based Telehealth and AI for Dermatology.. Journal of Investigative Dermatology 2026

Listen at AudioScholar

Editor's Pick: Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial (British Journal of Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease therapeutics — from a new interleukin-36 antibody in pustular psoriasis to long-term JAK inhibition in eczema — plus consensus and guideline documents that tell you what to do when standard care fails, and a cluster of cutaneous oncology papers on melanoma, transplant skin cancer, and rare…

This week's papers:

1. Efficacy and Safety of Recibokibart, an Interleukin-36 Receptor Antibody, in Generalized Pustular Psoriasis: A Phase 2 Randomized Trial.. British Journal of Dermatology 2026
2. 52-week ivarmacitinib in moderate-to-severe atopic dermatitis: A phase 3 trial.. Journal of the European Academy of Dermatology and Venereology 2026
3. RANDOMIZED CONTROLLED STUDY OF NEMOLIZUMAB IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ASSOCIATED PRURITUS: NIKAIA-1.. Journal of the American Academy of Dermatology 2026
4. Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults.. JAMA Dermatology 2026
5. Guidelines for diagnostic testing in adults with presumed atopic dermatitis refractory to treatment.. Journal of the American Academy of Dermatology 2026
6. Five-year survival impact of adjuvant anti-PD-1 therapy in a nationwide cohort of stage III melanoma.. Journal of the European Academy of Dermatology and Venereology 2026
7. Comparison of Pleomorphic Dermal Sarcoma to Advanced Cutaneous Squamous Cell Carcinoma and Soft-Tissue Sarcoma.. JAMA Dermatology 2026
8. HPV-Associated Cutaneous Malignancies in Solid Organ Transplant Recipients: Identification and the Role of the Dermatologist: Part 1.. Journal of the American Academy of Dermatology 2026
9. HPV-Associated Cutaneous Malignancy in Solid Organ Transplant Recipients: The Role of the Dermatologist in Management and Prevention: Part II.. Journal of the American Academy of Dermatology 2026
10. Clinicopathologic Characteristics, Treatment Outcomes of Pediatric Mycosis Fungoides in Turkey: A National Multicenter Retrospective Cohort.. Pediatric Dermatology 2026

Listen at AudioScholar

Editor's Pick: Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial (JAMA Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic drug safety and the cardiometabolic interface, new targeted therapy data in inflammatory and neutrophilic skin disease, risk stratification in skin cancer, and a pair of papers that together make a strong case for looking below the neck in acne. Let's dive in.

This week's papers:

1. Cardiometabolic Associations of Dermatological Treatments. Part I: Systemic Therapies.. Journal of the American Academy of Dermatology 2026
2. Cardiometabolic Associations of Dermatological Treatments. Part II: Targeted and Biologic Therapies.. Journal of the American Academy of Dermatology 2026
3. Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis: Secondary Analysis of a Phase 3 Randomized Clinical Trial.. JAMA Dermatology 2026
4. A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis.. Acta Dermato-Venereologica 2026
5. Validation of the integrated 40-gene expression profile (i40-GEP) which provides prognostic and adjuvant radiation benefit for high-risk cutaneous squamous cell carcinoma.. Journal of the American Academy of Dermatology 2026
6. Comorbidity-Guided Management of Pyoderma Gangrenosum: A Clinical Guide to Emerging Therapeutic Targets.. Journal of the American Academy of Dermatology 2026
7. Global Disparities in Access to Dermatological Care.. JAMA Dermatology 2026
8. Laser and Energy-Based Device Use in Skin of Color: A Clinical Review of Safety, Efficacy, and Best Practices.. Journal of the American Academy of Dermatology 2026
9. Truncal Acne Is Independently Associated with Stigmatization, Poorer Treatment Adherence and Greater Healthcare Utilization: A 20-country Survey.. Acta Dermato-Venereologica 2026
10. Effectiveness, safety and tolerability of Ozenoxacin 2% lotion vs Clindamycin 1% lotion in mild to moderate truncal acne: An open label randomized controlled clinical trial.. Clinical and Experimental Dermatology 2026

Listen at AudioScholar

Editor's Pick: Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients (Journal of the European Academy of Dermatology and Venereology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory skin disease and its systemic burden, new mechanisms and management frameworks in atopic dermatitis and alopecia areata, and diagnostics for the conditions we most often miss — subclinical basal cell carcinoma, VEXAS syndrome, and male genital lichen sclerosus. Let's dive in.

This week's papers:

1. Rezpegaldesleukin treatment of moderate-to-severe atopic dermatitis (REZOLVE-AD): final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomised phase 2b study.. The Lancet 2026
2. European S2k guidelines for hidradenitis suppurativa/acne inversa Part 1. Epidemiology, diagnosis and clinical assessment.. Journal of the European Academy of Dermatology and Venereology 2026
3. Alopecia areata: Emerging therapies and up-to-date management strategies.. Journal of the American Academy of Dermatology 2026
4. VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 1: Epidemiology, Pathophysiology, and Clinical Presentations.. Journal of the American Academy of Dermatology 2026
5. VEXAS Syndrome: A Comprehensive Review for Dermatologists Part 2: Work-up, Diagnosis, Treatment, and Prognosis.. Journal of the American Academy of Dermatology 2026
6. AI-Assisted Line-Field Confocal Optical Coherence Tomography to Detect Subclinical Basal Cell Carcinoma.. JAMA Dermatology 2026
7. Male genital lichen sclerosus.. Journal of the European Academy of Dermatology and Venereology 2026
8. Alopecia Areata: Advances in Clinical Evaluation and Pathogenesis.. Journal of the American Academy of Dermatology 2026
9. Factors influencing quality of life in hidradenitis suppurativa: Data from 1188 patients.. Journal of the European Academy of Dermatology and Venereology 2026
10. Cardiovascular Risk Factors in Adults with Atopic Dermatitis: A Cross-sectional Study.. Acta Dermato-Venereologica 2026

Listen at AudioScholar

Editor's Pick: Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies (The Lancet, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning the expanding reach of oral JAK inhibitors into vitiligo and alopecia areata, safety and risk stratification at the intersection of skin disease and cancer, and evolving standards for how we define and deliver care in atopic dermatitis and scarring. Let's dive in.

This week's papers:

1. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.. The Lancet 2026
2. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.. JAMA Dermatology 2026
3. Targeted therapies for psoriasis and atopic dermatitis in the context of malignancy: SPIN-FRT recommendations.. Journal of the European Academy of Dermatology and Venereology 2026
4. Alopecia areata as a sentinel condition for systemic autoimmunity: a global bidirectional cohort study.. Dermatology 2026
5. Risk Stratification Models for Cutaneous Malignant Neoplasms After Blood or Marrow Transplant.. JAMA Dermatology 2026
6. Relapse of Alopecia Areata During Ongoing JAK Inhibitor Therapy Is Not Uncommon and Usually Occurs in Previously Affected Areas: A Multicentre Italian Real-World Study.. Journal of the American Academy of Dermatology 2026
7. Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis.. Acta Dermato-Venereologica 2026
8. Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.. Acta Dermato-Venereologica 2026
9. Consensus on energy-based devices for keloids and hypertrophic scars: A Latin American Delphi study.. Journal of the European Academy of Dermatology and Venereology 2026
10. Immunosuppression Outweighs Clinical AEIOU Heuristics in Predicting Disease Progression of Merkel Cell Carcinoma: A Retrospective Cohort Study.. Acta Dermato-Venereologica 2026

Listen at AudioScholar

Editor's Pick: Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa (JAMA Dermatology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning inflammatory disease classification and the economics of biologics, real-world outcomes in atopic dermatitis and psoriasis, and a cluster of practical papers on infection, hair loss, and melanocytic lesion surveillance. Let's dive in.

This week's papers:

1. Pyoderma Gangrenosum Phenotype Classification. JAMA Dermatology 2026
2. Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa. JAMA Dermatology 2026
3. Treatment of tinea capitis in China: a multicenter prospective real-world study. Journal of the American Academy of Dermatology 2026
4. Risk-adapted monitoring of melanocytic lesions with peripheral globules: a longitudinal cohort study on melanoma risk stratification. Journal of the American Academy of Dermatology 2026
5. Systemic Comorbidities in Central Centrifugal Cicatricial Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica 2026
6. Psoriatic patients with cancer: a multicentric real-life study comparing Risankizumab and Apremilast. Dermatology 2026
7. Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study. Clinical and Experimental Dermatology 2026
8. Staphylococcal Scalded Skin Syndrome Often Does Not Require Empiric Coverage for Methicillin Resistance. Pediatric Dermatology 2026
9. Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis. Acta Dermato-Venereologica 2026
10. Improvement of Depressive and Fatigue Symptoms under Dupilumab Therapy in Atopic Dermatitis Patients: Results from the TREATgermany Registry. Acta Dermato-Venereologica 2026

Listen at AudioScholar

Editor's Pick: Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study (Journal of the American Academy of Dermatology, 2026)

Welcome to This Week in Dermatology. This week we are covering five notable papers spanning therapeutic advances and laboratory monitoring in alopecia areata, demographic variations in contact allergen sensitivities, multidimensional success metrics in hidradenitis suppurativa, and a critical update to the global naming system for biological therapies. Let's dive in.

This week's papers:

1. Clinical Yield of Laboratory Monitoring During Ritlecitinib Treatment for Alopecia Areata: A Prospective Real-World Cohort Study. Journal of the American Academy of Dermatology 2026
2. The Association of Race and Ethnicity with Patch Test Results: North American Contact Dermatitis Group Data, 2007-2020. Journal of the American Academy of Dermatology 2026
3. Long-term Efficacy and Safety of Upadacitinib in the Treatment of Alopecia Areata: A Retrospective Study. Journal of the American Academy of Dermatology 2026
4. Measuring success in HS treatment from the physician's and the patient's perspective. Journal of the European Academy of Dermatology and Venereology 2026
5. Decoding Biological Drug Names in Dermatology: The Post-2022 WHO Nomenclature Revision and Its Implications for Clinical Practice. Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Editor's Pick: Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials (Nature medicine, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic therapeutics for inflammatory skin disease, diagnostic imaging innovations, and pediatric and supportive care. Let's dive in. We begin with major advances in systemic therapies for inflammatory conditions and cutaneous oncology.

This week's papers:

1. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.. Nature medicine 2026
2. Clinical and Dermoscopic Triage of head and neck Macules: The Role of Reflectance Confocal Microscopy in a Prospective Study of 2006 Lesions.. Journal of the American Academy of Dermatology 2026
3. Comparative effects of interventions for rosacea across phenotype-relevant outcomes: a systematic review and network meta-analysis.. Journal of the American Academy of Dermatology 2026
4. Insulin Resistance is Not a Predictor of Response to Low-Dose Oral Metformin Therapy in Patients with CCCA: A Retrospective Review.. Journal of the American Academy of Dermatology 2026
5. Magnified ultraviolet-induced fluorescence dermatoscopy for assessing mite viability in scabies.. Journal of the American Academy of Dermatology 2026
6. Initial Psychometric Validation of the Caregiver Atopic Dermatitis Control Tool.. Clinical and experimental dermatology 2026
7. High Level of Uncertainty in Assigning Causative Medications in Drug Reaction with Eosinophilia and Systemic Symptoms: A Retrospective Cohort Analysis.. Journal of the American Academy of Dermatology 2026
8. A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations.. Pediatric dermatology 2026
9. Durable remission with no survival reduction after mogamulizumab discontinuation in Sézary syndrome.. The British journal of dermatology 2026
10. Cutaneous leishmaniasis in patients in treatment with anti-TNF-α drugs. Study of 20 cases from a single institution.. Clinical and experimental dermatology 2026

Listen at AudioScholar

Editor's Pick: Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study (Journal of the European Academy of Dermatology and Venereology, 2026)

Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning systemic manifestations and novel therapeutics in psoriasis, real-world outcomes in hair restoration, and emerging safety and diagnostic data in inflammatory dermatoses. Let's dive in. We begin with a deep look at psoriasis as a systemic disease and the potential for deep immunological resetting.

This week's papers:

1. Efficacy and safety of inhibitory magnetic stimulation in the treatment of refractory erythema of rosacea: a prospective, randomized, controlled clinical trial.. Journal of the American Academy of Dermatology 2026
2. Long-term Real-world Outcomes and Tolerability of Baricitinib in Alopecia Areata, Totalis, and Universalis: A Retrospective Single-center Cohort of 330 Patients with Trichoscopy Monitoring.. Journal of the American Academy of Dermatology 2026
3. Increased Efficacy of Daytime Low-dose Oral Minoxidil Dosing for Androgenetic Alopecia: A Retrospective Study.. The British journal of dermatology 2026
4. Cardiac structure and function in psoriasis: A cross-sectional analysis of the PSOCADIA study.. Journal of the European Academy of Dermatology and Venereology 2026
5. Malignant transformation in mucosal lichen planus: A 10-year, single-center, descriptive cohort analysis.. Journal of the American Academy of Dermatology 2026
6. Pemphigoid was not associated with increased risk of solid organ, hematologic, or nonmelanoma skin malignancies in a nationally representative matched cohort.. Clinical and experimental dermatology 2026
7. Relapse prediction in rituximab-treated pemphigus patients: A prognostic model.. Journal of the European Academy of Dermatology and Venereology 2026
8. Effect of semaglutide on hidradenitis suppurativa disease control and quality of life: A case series.. Journal of the European Academy of Dermatology and Venereology 2026
9. Missed melanoma following skin lesion triage by an autonomous artificial intelligence system in a community setting.. Clinical and experimental dermatology 2026
10. Long-term Remission of Severe Psoriasis Following CD19 CAR-T Cell Therapy for Follicular Lymphoma.. Clinical and experimental dermatology 2026

Listen at AudioScholar

Editor's Pick: Recurrence of Basal Cell Carcinoma across Different Treatment Modalities: A Nationwide Study with 8 Years of Follow-up and Modelled Prediction (Acta dermato-venereologica, 2026)

Welcome to This Week in Dermatology. This week we are covering ten notable papers spanning advanced management strategies for skin cancer, novel therapeutic insights in atopic dermatitis, and optimizing procedural and wound care outcomes. Let us dive in.

This week's papers:

1. Compression therapies for venous leg ulcers: The VENous Ulcer Study 6 (VenUS 6), an open, multicentre, randomised clinical trial.. PLoS medicine 2026
2. Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison.. Journal of the American Academy of Dermatology 2026
3. Recurrence of Basal Cell Carcinoma across Different Treatment Modalities: A Nationwide Study with 8 Years of Follow-up and Modelled Prediction.. Acta dermato-venereologica 2026
4. Acneiform Eruption with Deucravacitinib: Systematic Review and Meta-Analysis.. Clinical and experimental dermatology 2026
5. Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.. Clinical and experimental dermatology 2026
6. Clinical Predictors and a Novel Diagnostic Nomogram for Non-Bullous Pemphigoid: A 10-year Large-Scale Retrospective Case-Control Study.. Journal of the American Academy of Dermatology 2026
7. Resource Use and Cost Comparison of Mohs Micrographic Surgery vs Traditional Surgery for High-risk Facial Basal Cell Carcinoma.. Acta dermato-venereologica 2026
8. Compression Response During Ultrasound Aids Real-Time Differentiation of Pseudocysts and Tunnels in Hidradenitis Suppurativa.. Journal of the American Academy of Dermatology 2026
9. Assessing Skin Cancer Risk in Systemic Sclerosis Patients with Organ Transplantation: A Cohort Study.. Journal of the American Academy of Dermatology 2026
10. Near-Infrared Vascular Mapping to Guide Procedural Management of Superficial Cutaneous Vascular Lesions.. Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Editor's Pick: Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials (The British journal of dermatology, 2026)

Welcome to This Week in Dermatology. This week we are covering seven notable papers spanning novel oral therapeutics for psoriasis, hair loss interventions, and complex dermatopathological entities. Let's dive in. We begin with a major development in the management of moderate-to-severe plaque psoriasis.

This week's papers:

1. Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.. The British journal of dermatology 2026
2. Comparative risk of reactivation of hepatitis B and C after treatment with biologics and targeted synthetic DMARDs in psoriasis and psoriatic arthritis: a 15-year multicenter cohort study.. Journal of the American Academy of Dermatology 2026
3. Safety of Biologic Therapy in Psoriasis Patients With Malignancy.. Journal of the American Academy of Dermatology 2026
4. Comparative Alopecia Outcomes After Copper and Hormonal Intrauterine Device Placement: A TriNetX Database Retrospective Cohort Study.. Journal of the American Academy of Dermatology 2026
5. Microneedling with adipose MSC exosomes versus monotherapy for androgenetic alopecia.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026
6. Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients.. The British journal of dermatology 2026
7. Genomic Predictors of Perineural Invasion in Cutaneous Squamous Cell Carcinoma: Insights from an MD Anderson Cohort.. Journal of the American Academy of Dermatology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 9 notable papers spanning atopic dermatitis prevention and management, the systemic and behavioral burdens of chronic inflammatory skin diseases, and new insights into cutaneous biology and onco-dermatology. Let's dive in.

This week's papers:

1. Proteomic analysis in hidradenitis suppurativa reveals systemic inflammation in all disease stages.. Journal of the European Academy of Dermatology and Venereology 2026
2. Addiction in chronic inflammatory skin diseases: A systematic review of prevalence, impact and screening practices.. Journal of the European Academy of Dermatology and Venereology 2026
3. Human keratinocytes and fibroblasts coordinate early cutaneous innate defenses against Candida auris.. The Journal of Investigative Dermatology 2026
4. The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue.. The Journal of Investigative Dermatology 2026
5. Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled Trial.. The Journal of Investigative Dermatology 2026
6. Randomised Controlled Feasibility Trial of an Intervention to Reduce Infant Bathing.. The British Journal of Dermatology 2026
7. Male genital fixed drug eruption: a systematic review.. Clinical and Experimental Dermatology 2026
8. Treatment Trajectories and Dose Optimization of Abrocitinib in Moderate-to-Severe Atopic Dermatitis: A Real-World Landmark Analysis.. Clinical and Experimental Dermatology 2026
9. Metabolic determinants of cancer immunotherapy outcomes identified by plasma profiling.. Nature Medicine 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering nine notable papers spanning clinical screening strategies, advanced therapeutics for severe autoimmune and inflammatory conditions, and emerging prognostic models in patient care. Let's dive in.

This week's papers:

1. Outcomes of dermatologist-performed skin cancer screening in an academic setting: a retrospective cohort study.. Journal of the American Academy of Dermatology 2026
2. Cobratide injection vs Pregabalin for Moderate-to-Severe Acute Herpes Zoster Neuralgia: A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Multicenter Exploratory Trial.. Journal of the American Academy of Dermatology 2026
3. OX40 pathway inhibition and Kaposi sarcoma: An emerging safety signal in atopic dermatitis.. Journal of the European Academy of Dermatology and Venereology 2026
4. Isotretinoin is not associated with elevated risk of pseudotumor cerebri: A Danish register-based cohort study.. Journal of the American Academy of Dermatology 2026
5. Diagnosis and management of acyclovir-resistant herpes simplex virus for the dermatologist.. Journal of the American Academy of Dermatology 2026
6. Autoimmune Disease in Central Centrifugal Cicatricial Alopecia: A Multi-Institutional Cross-Sectional Study.. Journal of the American Academy of Dermatology 2026
7. Barbed Suture-Assisted High-Tension Cutaneous Closure: Brief Report of 493 Surgical Defects.. Journal of the American Academy of Dermatology 2026
8. Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.. The Journal of investigative dermatology 2026
9. Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic review.. Journal of the European Academy of Dermatology and Venereology 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 7 notable papers spanning the rise and real-world performance of artificial intelligence, new approaches to prognostication in inflammatory disease and skin cancer, and the complex landscape of genodermatoses from molecular mechanisms to patient counseling. Let's dive in. We begin with a major theme this week: artificial intelligence.

This week's papers:

1. General-purpose large language models outperform specialized clinical AI tools on medical benchmarks.. Nature medicine 2026
2. An ITGB4 variant modifies the severity of ITGA3-associated interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa (ILNEB).. The Journal of investigative dermatology 2026
3. Expanding histopathological assessment may provide limited prognostic value for metastatic cutaneous squamous cell carcinoma: insights from two nationwide nested case-control studies.. The British journal of dermatology 2026
4. Effectiveness and safety of hematoporphyrin monomethyl ether-mediated photodynamic therapy versus pulsed dye laser for port-wine stain: a retrospective study.. Journal of the American Academy of Dermatology 2026
5. Microdialysis-based metabolomic and proteomic profiling reveals signature variations for disease severity in psoriasis.. The Journal of investigative dermatology 2026
6. Artificial intelligence in dermatology: Clinical promise and environmental impact.. The Journal of investigative dermatology 2026
7. Patient Perspectives, Unmet Needs and Dilemmas in Reproductive Decision-making for Genodermatoses: A Qualitative Interview Study.. Acta dermato-venereologica 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering several notable papers spanning the profound systemic and psychological burden of skin disease, and a critical look at cancer mortality in our high-risk transplant population. Let's dive in.

This week's papers:

1. Atopic dermatitis.. Nature reviews. Disease primers 2026
2. Skin cancer mortality in Australian and New Zealand kidney transplant recipients: A population-based cohort study using linked health data, 1990-2019.. The British journal of dermatology 2026
3. Suicidal ideation in patients with skin conditions: A multicentre European study.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026
4. Epidermal necrolysis sequelae: A cohort study on prevalence and risk factors.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 4 notable papers spanning the systemic burden of severe skin diseases and recent advances in therapeutics. Let's dive in. First, we examine the significant systemic impact and mortality associated with severe dermatoses, with two papers this week offering crucial insights for bullous pemphigoid and severe cutaneous adverse reactions.

This week's papers:

1. Cardiac involvement in severe cutaneous adverse reactions: a Retrospective Observational Cohort Study of DRESS and SJS/TEN at a major Australian tertiary hospital.. Clin Exp Dermatol 2026
2. Increased Mortality in Patients with Bullous Pemphigoid: A Nationwide Population-based Cohort Study of 5,738 Patients in Sweden.. Acta Derm Venereol 2026
3. Long-Term Efficacy and Safety of Oleogel-S10 (Birch Triterpenes) for Pediatric Patients With Epidermolysis Bullosa.. Pediatr Dermatol 2026
4. Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability.. Br J Dermatol 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 8 notable papers spanning acne management, new approaches to inflammatory skin disease, drug-induced bullous pemphigoid, and the standardization of teledermatology. Let's dive in. Acne Management: Addressing Patient Concerns We begin with two papers that address common and persistent questions in acne management.

This week's papers:

1. Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: evidence from a prospective case-control study supporting ECD-BP180 ELISA in reducing diagnostic delay.. Journal of the American Academy of Dermatology 2026
2. A distinct psoriasis-atopic dermatitis overlapping phenotype in adults with dual type 2 and type 3 immune features and favorable response to JAK1 inhibition.. Journal of the American Academy of Dermatology 2026
3. Efficacy and Safety of Dupilumab in Immune Checkpoint Inhibitor Induced Bullous Pemphigoid: A Spanish Multicentric Case Series.. Acta dermato-venereologica 2026
4. European Expert Consensus on Essential Variables for Teledermatological Assessment of Skin Tumours.. Acta dermato-venereologica 2026
5. Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.. Acta dermato-venereologica 2026
6. Baricitinib versus Hydroxychloroquine for Cutaneous Lichen Planus: An Assessor-Blind Randomized Clinical Trial.. Clinical and experimental dermatology 2026
7. Isotretinoin Treatment in Adolescence and Adult Height.. JAMA dermatology 2026
8. Diet and acne: Facts and controversies.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026

Listen at AudioScholar

Welcome to This Week in Dermatology. This week we're covering 8 notable papers spanning advances in the management of inflammatory skin disease, innovations in diagnostics and procedures, and a key paper on health disparities in pediatric dermatology. Let's dive in.

This week's papers:

1. Treatment of androgenetic alopecia in transgender people receiving testosterone therapy with sublingual minoxidil: A randomized, double-blind, placebo-controlled clinical trial.. Journal of the American Academy of Dermatology 2026
2. Perioperative management in nail surgery: An international Delphi consensus statement.. Journal of the American Academy of Dermatology 2026
3. Evaluating T-Cell Clonality In Skin Using a Quantitative TRBC1-Clonality Score.. The Journal of investigative dermatology 2026
4. Diagnostic accuracy of two-photon fluorescence microscopy in Mohs surgery of basal cell carcinomas.. Journal of the American Academy of Dermatology 2026
5. New Hidradenitis Suppurativa in Children: Influence of Neighborhood Socioeconomic Status.. Pediatric dermatology 2026
6. Treatment-associated phenotype switching between psoriasis and atopic dermatitis.. Journal of the European Academy of Dermatology and Venereology : JEADV 2026
7. Text Messaging for Cardiovascular Risk Prevention in Psoriasis: A Randomized Clinical Trial.. JAMA dermatology 2026
8. Intraocular Pressure During Short-Term Topical or Systemic Corticosteroid Treatment: Analysis of 3 Randomized Clinical Trials.. JAMA dermatology 2026

Listen at AudioScholar